
Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing. Now, injected Wegovy could prove a boon for many patients battling heart failure, a new study suggests. The trial results were presented Friday in Amsterdam at the annual meeting of… read on > read on >